News & Updates

Show Multimedia Only

SPOTLIGHT: Durvalumab shines in real-world trial on NSCLC

21 Apr 2022 by

Findings from the SPOTLIGHT trial have shown the efficacy of administering durvalumab after chemoradiotherapy (CRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).

21 Apr 2022

Tislelizumab a potential treatment alternative for gynaecologic MSI-H/dMMR tumours

20 Apr 2022 by

The humanized IgG4 monoclonal antibody tislelizumab was clinically active in women with gynaecologic microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) solid tumours, and was generally well-tolerated with no new safety signals, according to a subgroup analysis of the phase II RATIONALE 209 study presented at SGO 2022.

20 Apr 2022

Resting energy expenditure confers breast cancer risk

20 Apr 2022

High resting energy expenditure (REE) contributes to an increase in the risk of invasive breast cancer among postmenopausal women, as reported in a study.

20 Apr 2022

Night shift tied to lower prostate cancer risk among selected men

20 Apr 2022

Men who carry the G allele of melatonin receptor 1B gene (MTNR1B) rs10830963 are at lower risk of prostate cancer when exposed to night shift work, according to a study.

20 Apr 2022

Income, comorbidity predict inferior vena cava filter placement, retrieval in cancer patients

19 Apr 2022

Income and several clinical factors are associated with placement and retrieval of inferior vena cava filter for patients with cancer-related thrombosis, a study has found. In addition, filter retrieval rates remain low despite reinitiation of anticoagulation in many patients.

19 Apr 2022

Cancer risk elevated in mild-to-moderate CKD patients, transplant recipients

19 Apr 2022

There appears to be a substantial cancer incidence in the setting of kidney disease, with cancer risk heightened among patients with mild-to-moderate chronic kidney disease (CKD) and transplant recipients, but not among those with advanced kidney disease, according to a study.

19 Apr 2022

Androgen deprivation therapy for prostate cancer ups dementia risk

18 Apr 2022 by

Adult men with prostate cancer who have increasing exposure to androgen deprivation therapy (ADT) are at greater risk of dementia, according to a US study.

18 Apr 2022

Original New Drug Application Approvals by US FDA (01 - 15 April 2022)

18 Apr 2022

New drug applications approved by US FDA as of 01-15 April 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

18 Apr 2022

High-intensity training eases anxiety, stress in prostate cancer

17 Apr 2022

A supervised high-intensity interval training (HIIT) program for 12 weeks leads to improvements in prostate cancer-specific anxiety, fear of cancer progression, hormone symptoms, stress, fatigue, and self-esteem in men on active surveillance, reports a study.

17 Apr 2022

Secondary primary malignancies worsen multiple myeloma survival

16 Apr 2022

While survival among multiple myeloma patients has been improving over time, the development of secondary primary malignancies seems to offset this effect by increasing the risk of mortality, a recent study has found.

16 Apr 2022

News & Updates

Showing Oncology articles

Showing

Specialty:

SPOTLIGHT: Durvalumab shines in real-world trial on NSCLC

Tislelizumab a potential treatment alternative for gynaecologic MSI-H/dMMR tumours

Resting energy expenditure confers breast cancer risk

Night shift tied to lower prostate cancer risk among selected men

Income, comorbidity predict inferior vena cava filter placement, retrieval in cancer patients

Cancer risk elevated in mild-to-moderate CKD patients, transplant recipients

Androgen deprivation therapy for prostate cancer ups dementia risk

Original New Drug Application Approvals by US FDA (01 - 15 April 2022)

High-intensity training eases anxiety, stress in prostate cancer

Secondary primary malignancies worsen multiple myeloma survival